RxDoctor Payments Data

Joel Salter

Family · Gilbert, AZNPI 1487831129

Payments from drug & device makers

$2,990in general payments, 2019–2025

Across 153 payments — averaging $19.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Abbott$216
  • Indivior Inc.$203
  • Lilly USA, LLC$195
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$160
  • Otsuka America Pharmaceutical, Inc.$150
  • plus $916 from 23 others

What the payments were for

  • Food & beverage$2,94899%
  • Education$421%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,990 in reported general payments places this provider in the 85th percentile of 4,119 family providers in Arizona.

See all family providers in Arizona

Medicare billing

Part B allowed, 2024
$93,098
Medicare patients
71
Services billed
10,198

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XeljanzTofacitinib Citrate12$79,680
MounjaroTirzepatide26$28,092
Emgality PenGalcanezumab-Gnlm18$12,921
Xtampza ErOxycodone Myristate12$8,564
Permethrin11$3,025
Oxycodone Hcl116$2,756
Wixela InhubFluticasone Propion/Salmeterol13$2,273
Malathion15$1,364
Buprenorphine Hcl41$1,199
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen28$1,156
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine33$1,126
Gabapentin97$1,008
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen38$764
Zolpidem Tartrate81$656
Albuterol Sulfate HfaAlbuterol Sulfate32$653

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerXeljanz$33$79,68012 claims
Lilly USA, LLCMounjaro$195$28,09226 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,119 family providers in Arizona.

Other family in Gilbert

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →